With OTC Lidocaine, Salonpas Takes Path Of Less Resistance To Market
Hisamitsu America looked to the OTC lidocaine market after deciding it would have to wait too long for an ANDA approval for an Rx generic. "We really saw the opportunity in the OTC space with a 4% OTC patch," says President and CEO John Incledon.
You may also be interested in...
Hisamitsu America launches online portal exclusively for health care professionals. Also in OTC topical space, Beutlich Pharmaceuticals extends HurriCaine benzocaine gel and spray line with oral anesthetic single-dose packages in five flavors.
Hisamitsu America launches Salonpas Arthritis Pain Relief Gel with same active ingredient, diclofenac sodium 1% gel, that became available OTC for the first time in the US in 2020 with GSK’s Voltaren Arthritis Pain formulation.
Hisamitsu America’s severity of pain claims for Salonpas challenged by GSK are more nuanced than what label indications support, but touting its regulatory approval doesn’t convey a message that other products aren’t subject to as rigorous pre-market evaluations.